We are live on ! Find out more
SNDX icon

Syndax Pharmaceuticals
SNDX

80 hedge funds and large institutions have $150M invested in Syndax Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 27 increasing their positions, 19 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 9

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

42% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 19

18% more funds holding

Funds holding: 68 → 80 (+12)

2.74% more ownership

Funds ownership: 67.67% → 70.41% (+2.7%)

15% less capital invested

Capital invested by funds: $176M → $150M (-$25.6M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $9K

Holders
80
Holders Change
+12
Holders Change %
+17.65%
% of All Funds
1.81%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
21
Increased
27
Reduced
19
Closed
9
Calls
–
Puts
$9K
Net Calls
-$9K
Net Calls Change
-$9K

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$32M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$3.08M
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$1.67M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$862K
5
OAM
Oxford Asset Management
United Kingdom
+$858K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$7.94M
2
ACH
ArrowMark Colorado Holdings
Colorado
-$5.82M
3
Jennison Associates
Jennison Associates
New York
-$4.16M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.91M
5
EAM
Eventide Asset Management
Massachusetts
-$2.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
PAM
26
Panagora Asset Management
Massachusetts
$710K +$802K +81,056 New
JGC
27
J. Goldman & Co
New York
$622K +$188K +19,000 +37%
CS
28
Candriam SCA
Luxembourg
$613K +$693K +70,000 New
ACM
29
Asymmetry Capital Management
California
$539K +$609K +61,530 New
Goldman Sachs
30
Goldman Sachs
New York
$515K +$581K +58,747 New
PP
31
PDT Partners
New York
$496K +$561K +56,655 New
MCIM
32
Meadow Creek Investment Management
Georgia
$482K -$60.2K -6,086 -10%
TCIM
33
TIAA CREF Investment Management
New York
$468K +$32.7K +3,304 +7%
Los Angeles Capital Management
34
Los Angeles Capital Management
California
$451K +$372K +37,549 +270%
BCM
35
Bridgeway Capital Management
Texas
$442K – – –
Balyasny Asset Management
36
Balyasny Asset Management
Illinois
$428K +$483K +48,806 New
EP
37
Elkfork Partners
Oregon
$397K -$49.6K -5,012 -10%
Bank of New York Mellon
38
Bank of New York Mellon
New York
$396K -$23.3K -2,356 -5%
Deutsche Bank
39
Deutsche Bank
Germany
$369K +$170K +17,213 +69%
TI
40
Trexquant Investment
Connecticut
$353K +$286K +28,923 +255%
GHCM
41
Glen Harbor Capital Management
California
$312K -$39K -3,938 -10%
PCM
42
Prelude Capital Management
New York
$284K +$320K +32,366 New
Two Sigma Investments
43
Two Sigma Investments
New York
$271K +$306K +30,930 New
HCM
44
Highbridge Capital Management
New York
$248K +$280K +28,328 New
AA
45
ALPS Advisors
Colorado
$237K +$50.9K +5,143 +24%
AQR Capital Management
46
AQR Capital Management
Connecticut
$228K -$70.5K -7,121 -21%
NA
47
Neuburgh Advisers
California
$227K -$28.3K -2,864 -10%
Renaissance Technologies
48
Renaissance Technologies
New York
$225K +$254K +25,700 New
Charles Schwab
49
Charles Schwab
California
$214K – – –
D.E. Shaw & Co
50
D.E. Shaw & Co
New York
$202K +$73.6K +7,433 +48%
1
2
3 4

SNDX Hedge Fund Activity: Q4 2017 in Review

80 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q4 2017, worth a combined $150M — down 15% from $176M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new SNDX positions and 9 closed out — a net gain of 12 holders — while 27 added to existing stakes and 19 trimmed.

The largest buyer was BVF Inc, opening a new position worth an estimated $32M. The largest seller was BlackRock, cutting an estimated $7.94M.

  • 80 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q4 2017, up from 68 in Q3 2017.
  • Funds reported $150M of Syndax Pharmaceuticals stock for Q4 2017, down 15% quarter-over-quarter.
  • 21 funds opened new Syndax Pharmaceuticals positions in Q4 2017 and 9 closed out, a net change of +12 holders.
  • The largest Syndax Pharmaceuticals buyer in Q4 2017 was BVF Inc, an estimated $32M added.
  • The largest Syndax Pharmaceuticals seller in Q4 2017 was BlackRock, an estimated $7.94M sold.

Based on aggregated 13F filings for Q4 2017.